{"id":3333,"date":"2020-12-14T07:30:23","date_gmt":"2020-12-14T07:30:23","guid":{"rendered":"http:\/\/dev.sunpharma.com\/?page_id=3333"},"modified":"2026-05-08T19:52:28","modified_gmt":"2026-05-08T14:22:28","slug":"investors-statutory-communications","status":"publish","type":"page","link":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","title":{"rendered":"Investors &#8211; Statutory Communications"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.16&#8243; background_image=&#8221;https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/investor-banner.jpg&#8221; parallax=&#8221;on&#8221; da_disable_devices=&#8221;off|off|off&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_fullwidth_header title=&#8221;Investor Information&#8221; header_fullscreen=&#8221;on&#8221; button_one_url=&#8221;#visionvalues&#8221; button_two_url=&#8221;#codeofconduct&#8221; _builder_version=&#8221;4.16&#8243; title_font=&#8221;|700|||||||&#8221; title_text_color=&#8221;#f7941e&#8221; title_font_size=&#8221;40px&#8221; title_line_height=&#8221;1.2em&#8221; content_font=&#8221;||||||||&#8221; content_text_color=&#8221;#000000&#8243; content_line_height=&#8221;1.8em&#8221; subhead_font=&#8221;||||||||&#8221; subhead_text_color=&#8221;rgba(0,0,0,0.6)&#8221; subhead_font_size=&#8221;22px&#8221; subhead_line_height=&#8221;1.4em&#8221; background_color=&#8221;rgba(255,255,255,0.7)&#8221; custom_button_one=&#8221;on&#8221; button_one_text_size=&#8221;20px&#8221; button_one_text_color=&#8221;#ffffff&#8221; button_one_bg_color=&#8221;#f7941e&#8221; button_one_border_width=&#8221;0px&#8221; button_one_font=&#8221;|||on|||||&#8221; button_one_use_icon=&#8221;off&#8221; custom_button_two=&#8221;on&#8221; button_two_text_size=&#8221;20px&#8221; button_two_text_color=&#8221;rgba(0,0,0,0.7)&#8221; button_two_bg_color=&#8221;#ffffff&#8221; button_two_border_width=&#8221;0px&#8221; button_two_font=&#8221;|||on|||||&#8221; button_two_use_icon=&#8221;off&#8221; button_two_custom_margin=&#8221;||||false|false&#8221; button_two_custom_margin_tablet=&#8221;&#8221; button_two_custom_margin_phone=&#8221;|||1px|false|false&#8221; button_two_custom_margin_last_edited=&#8221;on|desktop&#8221; button_two_custom_padding=&#8221;||||false|false&#8221; background_layout=&#8221;light&#8221; width=&#8221;50%&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;100%&#8221; width_last_edited=&#8221;on|phone&#8221; animation_style=&#8221;fade&#8221; animation_duration=&#8221;500ms&#8221; animation_delay=&#8221;300ms&#8221; title_font_tablet=&#8221;&#8221; title_font_phone=&#8221;&#8221; title_font_last_edited=&#8221;on|phone&#8221; content_font_tablet=&#8221;&#8221; content_font_phone=&#8221;&#8221; content_font_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; background_color=&#8221;rgba(0,0,0,0)&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; width=&#8221;90%&#8221; max_width=&#8221;2560px&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#f7941e&#8221; header_font_size=&#8221;25px&#8221; header_line_height=&#8221;1.2em&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#f7941e&#8221; header_2_font_size=&#8221;25px&#8221; header_2_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>Statutory Communications<\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;|700|||||||&#8221; header_text_color=&#8221;#f7941e&#8221; header_font_size=&#8221;25px&#8221; header_line_height=&#8221;1.2em&#8221; header_2_font=&#8221;|700|||||||&#8221; header_2_text_color=&#8221;#f7941e&#8221; header_2_font_size=&#8221;25px&#8221; header_2_line_height=&#8221;1.2em&#8221; custom_margin=&#8221;||12px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_text][et_pb_tabs _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; body_text_color=&#8221;#000000&#8243; body_line_height=&#8221;1.8em&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_tab title=&#8221;2026&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/05\/Scrutinizer-Report-of-Postal-Ballot-E-voting-April-2026.pdf\">Scrutinizer Report of Postal Ballot E-voting April 2026<br \/>\n <\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/05\/IntimationSE20260505OrganonAcquisitionTranscript_Signed.pdf\">Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon &#038; Co.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/IntimationSE20260427_Organon_Acquisition_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of investor call recording in relation to the acquisition of Organon &#038; Co<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/FY26-27April-2026-Investor-Call-Recording-Acquisition-of-Organon-Co.mp3\">Audio Recording Link for the investor call in relation to the acquisition of Organon &#038; Co.<br \/>\n<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/Scrutinizer-Report_1_Postal-Ballot_2026.pdf\">Scrutinizer Report of Postal Ballot\/E-voting March 2026<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/04\/Sun-Pharma-Notice-of-Postal-Ballot-and-Evoting-07042026.pdf\">Notice of Postal Ballot \/ E-voting (April 2026)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/03\/Sun-Pharma-Notice-of-Postal-Ballot-Mar-2026.pdf\">Notice of Postal Ballot \/ E-voting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/03\/SEIntimationSSSurveyonRTAServices.pdf\">Shareholder Satisfaction Survey on RTA Services<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/02\/IntimationSE20260203_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/02\/SEIntimationforSR.pdf\"> Sustainability Report F.Y. 2024-25<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2026\/01\/IntimationSE20260131_Q3FY26_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q3FY26 Earnings Call Audio Recording<\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2025&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251110_for_Analyst_and_Investor_meeting_signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251107_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/IntimationSE20251105_Q2FY26_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q2FY26 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/11\/Website-upload-RPT-for-HY-30-September-2025.pdf\">Related Party Transactions for the half year ended 30 September 2025<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/10\/seintimationforesg.pdf\">ESG Overview for FY2024-25<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/09\/IntimationSE20250918_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/09\/IntimationSE20250908_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250825_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250812_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/video\/CDSL_Sun%20Pharmaceutical%20Industries%20Limited_31072025%201.mp4\">Webcast Recording of 33rd Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/IntimationSE20250805_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/08\/ScrutinizersReportSD.pdf\">Intimation of Scrutinizers Report for 33rd Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/07\/IntimationSE20250731_Q1FY26_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q1FY26 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/06\/IntimationSE20250625_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/RPT-Disclosure-for-Website-Upload-as-on-31-March-2025-1.pdf\"><span>Related Party Transactions for the half year ended 31 March 2025<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/IntimationSE20250522_Q4FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q4FY25 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/05\/IntimationSE20250520_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/03\/Scrutinizer-Report_Postal-Ballot_Sun-Pharmaceutical-Industries-Limited_25-March-2025_signed.pdf\"><span>Scrutinizer Report for Postal Ballot\/E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/Sun-Pharma-Notice-of-Postal-Ballot-and-Evoting.pdf\"><span>Notice of Postal Ballot\/E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250207_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250204_for_Analyst_and_Investor_meeting1_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/IntimationSE20250204_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/02\/Sun-Pharma-Sustanability-Report-FY-2023-24.pdf\"><span>Sustainability Report F.Y. 2023-24<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2025\/01\/IntimationSE20250131_Q3FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q3FY25 Earnings Call Audio Recording<\/span><\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2024&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241203_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241111_for_Analyst_and_Investor_meeting_Signed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/11\/IntimationSE20241107_for_Analyst_and_Investor_meeting_Singed.pdf\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/10\/Related-Party-Transactions-for-the-half-year-ended-September-30-2024.pdf\"><span>Related Party Transactions for the half year ended September 30, 2024<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/10\/IntimationSE20241028_Q2FY25_Investor_Call_Recording_Signed.pdf\">Stock Exchange Letter Disclosure of Q2FY25 Earnings Call Audio Recording<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/09\/IntimationSE20240916_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240828_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/SEIntimationforESGOverview.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation regarding ESG Overview for the financial year 2023-24<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240813_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240807_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/cdsl-sun-pharmaceutical-industries-limited.mp4\"><span>Webcast Recording of 32<sup style=\"bottom: 0.5em;\">nd<\/sup>\u00a0Annual General Meeting of the Company<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/08\/IntimationSE20240801_Q1FY25_Investor_Call_Recording_Signed.pdf\"><span>Stock Exchange Letter Disclosure of Q1FY25 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/Information-shared-with-BSE.pdf\"><span>Information shared with BSE for Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><span><u><\/u><u><\/u><\/span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/Information-shared-with-NSE.pdf\"><span>Information shared with NSE for Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/BSE_Observation-letter-for-Scheme-of-Arrangement_24.06.2024.pdf\">BSE Observation Letter for <span>Composite\u00a0<\/span>Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/07\/NSE_Observation-letter-for-Scheme-of-Arrangement_24.06.2024.pdf\">NSE Observation Letter for <span>Composite\u00a0<\/span>Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/06\/TDS-Annexure-FY23-24.pdf\">Tax on Dividend for Final Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/06\/IntimationSE20240611_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240529_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240527_for_Analyst_and_Investor_meeting_Signed.pdf\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/RPT-for-Website-March-2024.pdf\">Related Party Transactions for the half year ended March 31, 2024<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/IntimationSE20240522_Q4FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q4FY24 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/Scrutinizer-Report_Postal-Ballot_Sun-Pharmaceutical-Industries-Limited.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scrutiniser Report on Postal Ballot<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/05\/Voting-Results.Website-upload.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"E-voting Results of Postal Ballot\"><span>E-voting Results of Postal Ballot<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/04\/Sun-Pharma-Notice-of-Postal-Ballot-E-voting..pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Notice of Postal Ballot &amp; E-voting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/03\/IntimationSE20240305_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/SEIntimationforsurvey.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Shareholder Satisfaction Survey<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/IntimationSE20240212_SunPharma_SandP_Sustainability_Yearbook_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sun Pharma included in S&amp;P Global Sustainability Yearbook 2024<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/02\/IntimationSE20240205_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/01\/IntimationSE20240131_Q3FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Disclosure of Q3FY24 Earnings Call Audio Recording<\/span><\/a>[\/et_pb_tab][et_pb_tab title=&#8221;2023&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2024\/03\/composite_scheme_of_arrangement.zip\"><span>Composite Scheme of Arrangement<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/Related-Party-Transaction-Report-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Related Party Transactions for the half year ended September 30, 2023<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/IntimationSE_20231101_Q2FY24_Investor_Call_Recording_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/10\/IntimationSigned-29.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Board Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/09\/IntimationSE20230918_for_Analyst_and_Investor_Meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Sun_Pharma_ESG-Overview_FY2022-23_Final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ESG Overview FY2022-23<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/CDSL_Sun_Pharma_28082023.mp4\" target=\"_blank\" rel=\"noopener noreferrer\">Webcast Recording of 31st Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Intimation-of-Schedule-of-Analyst-or-Institutional-Investor-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/Intimation-of-schedule-of-analyst-or-institutional-investor-meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/IntimationSE20230804_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/11\/Related-Party-Transaction-Report-2.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Related Party Transactions for the half year ended March 31, 2023<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/08\/IntimationSE20230803_Q1FY24_Investor_Call_Recording.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/07\/Annexure-for-Dividend-Tax.pdf\"><span>Tax on Dividend for Final Dividend<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/06\/Dividend-Waiver-Form.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Dividend Waiver Form<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/IntimationSE20230530AnalystMeetIntimationSinged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/span><\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/1AdditionalLetterSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update relating to earnings call<\/a><u><\/u><u><\/u><\/span><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/2SEIntimationSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel<\/a><u><\/u><u><\/u><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/3OutcomeDirectorsSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Appointment of Director<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/4IntinationSE20230527MeetingSchedule.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/span><\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/05\/IntimationSE20230526_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/04\/Intimation_Update-on-Maholi-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on US FDA Inspection at Mohali Facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/Intimationsigned-16.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on IT Security Incident<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSE20230314_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSE20230303_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/03\/IntimationSigned-10.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of IT Security Incident<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/Dividend-Waiver-Form_Interim-Dividend_2022-23.pdf\" target=\"_blank\" rel=\"noopener\">Interim Dividend Waiver Form for the financial year 2022-23<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/IntimationSE20230203_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2022&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/02\/IntimationSE20230131_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/01\/IntimationSigned-7.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of postal ballot and disclosure of voting results- Appointment of Mr. Sanjay Asher as an Independent Director<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2023\/01\/Sun-Pharma-Sustainability-Report-2021-22-NE.pdf\" target=\"_blank\" rel=\"noopener\">Sustainability Report 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/12\/Notice-of-Postal-Ballot-Form.pdf\" target=\"_blank\" rel=\"noopener\">Notice of Postal Ballot for Appointment of Mr. Sanjay Asher &amp; Postal Ballot Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/Related-Party-Transactions-for-half-year-ended-30.09.2022.pdf\" target=\"_blank\" rel=\"noopener\">Related Party Transactions for half year ended 30.09.2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/IntimationSE20221108_for_Analyst_and_Investor_meetingsigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/11\/IntimationSE20221101_Disclosure_Earnings_Call_Audio_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/09\/IntimationSE20220917_for_Analyst_and_Investor_meetingsigned-1.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/AGM_CDSL_Sun_Pharma_29082022.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording of 30th AGM<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSignedFinal.pdf\" target=\"_blank\" rel=\"noopener\">Voting Results and Scrutinizer\u2019s Report of 30th AGM<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Sun-Pharma-ESG-Overview-FY21-22.pdf\" target=\"_blank\" rel=\"noopener\">ESG Overview 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSE20220811_for_Analyst_and_Investor_meetingSigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationFinalSigned.pdf\" target=\"_blank\" rel=\"noopener\">Publication for 30th AGM and Evoting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSigned-2.pdf\" target=\"_blank\" rel=\"noopener\">Publication of 30th Annual General Meeting to be held by VC<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Form-for-waiver-forgoing-right-to-receice-Final-Dividend-for-financial-year-2021-22.pdf\" target=\"_blank\" rel=\"noopener\">Form for waiver-forgoing right to receive Final Dividend for financial year 2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/Retirement-of-Chairman.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 Retirement of Chairman<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/SPIL-Q1-2022-23.pdf\" target=\"_blank\" rel=\"noopener\">Publication of unaudited financial results for Q1<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/08\/IntimationSigned-1.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of the 30th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/IntimationSE20220729_Disclosure_Audio-_Call-_Q1FY23_signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/Self-Declaration-for-Non-resident-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Self-declaration for Non-resident Shareholder<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/Outcome-of-BM-29072022.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 July 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/07\/SPIL-SE-Intimation-of-BM_July_2022_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Board Meeting July 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Closure-of-Trading-Window-Q1-2022-23.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Closure of Trading Window Q1 (2022-23)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Related_Party_Disclosure_under_Reg_23_for_March_2022_signed_Final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Consolidated Related Party Transactions for half year ended 31.03.2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/IntimationSE20220602_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/IntimationSigned.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> Intimation under Regulation 30 \u2013 31 May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSE20220530_Disclosure_Earnings_Call_Audio.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Outcome30may2022.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation under Regulation 30 \u2013 30 May 2022 (Approval of Scheme of Amalgamation)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/Director.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation under Regulation 30 \u2013 30 May 2022 (Appointment of Lead Independent Director\/ Re-appointment of Directors)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/SPILASCR202122.pdf\" target=\"_blank\" rel=\"noopener\">Annual Secretarial Compliance Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSE20220524_for_Analyst_and_Investor_meeting_24_May_22_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/BMIntimation.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of Board Meeting May 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/05\/IntimationSigned.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 10th May, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/2-29th-March-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 29th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/SPIL-Intimation-under-Reg-30-March-21-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 March 21, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/4-8th-March-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 8th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/IntimationtoSEunderReg30dt22022022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 \u2013 February 22, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/6-1st-February-2022.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 1st February, 2022<br \/><\/a>\u00a0<br \/><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Press-Release-Phase-3-Data-for-WINLEVI-presents-at-the-AAD-Annual-Meeting.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 25th March, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Reg-30-Intimation-MoU-US-Ranbaxy-Litigation-23032022-Signed.pdf\" target=\"_blank\" rel=\"noopener\">Disclosure under Regulation 30 of SEBI Listing Regulations &#8211; Signing of Binding Memorandum of Understanding as to Material Terms of Settlement with the Direct Purchaser and End-Payor Plaintiffs in the In re Ranbaxy Generic Drug Application Antitrust Litigation in the U.S. District Court for the District of Massachusetts (USA)<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/Closure-of-trading-window.pdf\" target=\"_blank\" rel=\"noopener\">Closure of Trading Window<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/IntimationSE20220302_for_Analyst_and_Investor_meeting_08_Mar_22.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/02\/IntimationSE20220214_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/02\/IntimationSE20220205_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Interim-Dividend-Waiver-Form_2021-22.pdf\" target=\"_blank\" rel=\"noopener\">Interim Dividend Waiver Form_2021-22<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Outcome-of-Board-Meeting-held-on-31.01.2022.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on Jan 31, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Press-Release-Sun-Pharma-launches-CEQUA-in-Canada.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 27th January, 2022<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/01\/Intimationfinal.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting January 2022<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2021&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/12\/Press-Release-Sun-Pharma-receives-DCGI-approval-for-Molxvir-Molnupiravir-in-India.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 28th December, 2021<br \/> <\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/9-15th-December-2021.pdf\" target=\"_blank\" rel=\"noopener\"><\/a><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/9-15th-December-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 15th December, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/12\/consolidated-Half-year-ended-sept-21-RPT-Final-for-SE.pdf\" target=\"_blank\" rel=\"noopener\">Consolidated Related Party Transactions for half year ended 30.09.2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/10-30th-November-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 30th November, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211122_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211112_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Press-Release-Sun-Pharma-gearing-up-to-introduce-molnupiravir-under-the-brand-name-Molxvir\u00ae-in-India.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 11th November, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/IntimationSE20211109_for_Analyst_and_Investor_meeting.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Intimation-to-Stock-Exchanges-reg-GxMDL-antitrust-litigation-Final-5-11-....pdf\" target=\"_blank\" rel=\"noopener\">Signing of settlement agreements with the Direct Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania (USA) by our 2 subsidiary companies.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/11\/Outcome-of-Board-Meeting-held-on-Nov-02-2021.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on Nov 02, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/10\/ClosureofTradingwindow.pdf\" target=\"_blank\" rel=\"noopener\">Closure of trading window<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210928_for_Analyst_and_Investor_meeting_Signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210917_for_Analyst_and_Investor_meetingSigned.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Webcast-of-29th-AGM.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording of 29th Annual General Meeting of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Press-Release-Sun-Pharma-launches-Chericof-12.pdf\">Intimation under Regulation 30- 28th September, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Intimation-to-exchange-Sanction-of-Scheme-of-Amalgamation-and-Merger-of-Sun-Pharma-Global-FZE-with-SPIL.pdf\" target=\"_blank\" rel=\"noopener\">Intimation to exchange Sanction of Scheme of Amalgamation and Merger of Sun Pharma Global FZE with SPIL<\/a><\/p>\n<p><a href=\"&lt;a href=\">Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/IntimationSE20210907signed.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/Reg30resignation.pdf\" target=\"_blank\" rel=\"noopener\">Resignation of Mr. Vivek Channd Sehgal<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/03\/12-1st-September-2021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30- 1st September, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/29thAGMVotingResults.pdf\" target=\"_blank\" rel=\"noopener\">Voting Results of 29th AGM and Scrutiniser\u2019s Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/09\/CombinedOutcomeof29thAGMupload.pdf\" target=\"_blank\" rel=\"noopener\">Proceedings of 29th AGM and Intimation of Changes in Directors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Chairman-Speech-at-the-29th-Annual-General-Meeting-held-on-31-August-2021.pdf\" target=\"_blank\" rel=\"noopener\">Chairman Speech at the 29th Annual General Meeting held on 31 August 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Reg47NewspaperAdvtwithCoverletter.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice of 28th Annual General Meeting and E-voting \u2013 Post-dispatch<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/Form-for-waiver-forgoing-right-to-receice-Final-Dividend-for-financial-year-2020-21.pdf\" target=\"_blank\" rel=\"noopener\">Form for waiver-forgoing right to receive Final Dividend for financial year 2020-21<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/SPILReg47NewspaperIntPredispatch05082021.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure \u2013 Pre-dispatch<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/SPILAGMBookClosureIntimation04082021.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of AGM and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/08\/OutcomeBMJuly302021.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of Board Meeting held on July 30, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/07\/Newspaper-Advertisement-for-Notice-for-transfer-of-equity-shares-and-unclaimed-Dividend-to-IEPF.pdf\" target=\"_blank\" rel=\"noopener\">Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/07\/IntimationofBMQ1202122.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting July 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/04\/ASCR.pdf\" target=\"_blank\" rel=\"noopener\">Annual Secretarial Compliance Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2022\/06\/Consolidated-Related-Party-Transactions-for-half-year-ended-31.03.2021.pdf\" target=\"_blank\" rel=\"noopener\">Consolidated Related Party Transactions for half year ended 31.03.2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/06\/225_IntimationSE20210607.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimationSUNAZ28052021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation of Acquisition of trademarks and patent license for Dapagliflozin and its combinations from AstraZeneca AB<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/Stock-Exchange-Letter-Intimation-Schedule-of-Analyst-Fund-Meet.pdf\" target=\"_blank\" rel=\"noopener\">Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/Outcome27052021Final.pdf\" target=\"_blank\" rel=\"noopener\">Outcome of the Board Meeting \u2013 May 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimation20052021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation for Appointment of Additional Independent Directors on the Board of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/IntimationofBMQ410052021.pdf\" target=\"_blank\" rel=\"noopener\">SPIL Intimation of Board Meeting May 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/usa\/wp-content\/uploads\/sites\/2\/2021\/05\/IntimationtoStockExchange30042021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/usa\/wp-content\/uploads\/sites\/2\/2021\/05\/ReplytoStockExchangeMSDforMolnupiravir29042021Final.pdf\" target=\"_blank\" rel=\"noopener\">Clarification to Stock Exchanges on News Item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/04\/IntimationtoStockExchange06042021PharmarackUpdate.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/cdsl_sunpharma-share-holder.mp4\" target=\"_blank\" rel=\"noopener\">Webcast Recording for Tribunal Called Meeting of Equity Shareholders of the Company held on March 16, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/04\/IntimationtoStockExchange31032021AWACS.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/IntimationtoStockExchange25032021.pdf\" target=\"_blank\" rel=\"noopener\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/VotingResultsandScrutinizerReport18032021.pdf\">Voting Results of the NCLT Convened Meeting of Equity Shareholders held on March 16, 2021 and Scrutinizer\u2019s Reports<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/ProceedingsofNCLTconvenedmeetings16032021.pdf\">Proceedings of the NCLT Convened Meetings of Unsecured Creditors and Equity Shareholders held on March 16, 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/SPILStockExchangeIntimationWRSBioproductsUpdate10032021.pdf\">Update on Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/SPILStockExchangeIntimationWRSBioproducts05032021.pdf\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationtoSEforNewspaperAdvtofNCLTMeetingsCAA.pdf\">Newspaper Advertisement for NCLT Meetings of Equity Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationofSettlementOrdertoExchanges11022021-1.pdf\">Intimation Letter for Conclusion of settlement proceedings with SEBI<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Notice-of-NCLT-Convened-Meeting-of-Unsecured-Creditors-1.pdf\">Notice of NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Notice-of-NCLT-Convened-Meeting-of-Equity-Shareholders-1.pdf\">Notice of NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/NewspaperAdvertisementsubmission-30121-1.pdf\">Newspaper Advertisement for Intimation of Record Date for Payment of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_15G-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 15G<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/Interim-Dividend-Waiver-Form_2020-21-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Interim Dividend Waiver Form_2020-21<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_15H-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 15H<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/OutcomeofBoardMeeting290121-1.pdf\">Outcome of the Board Meeting \u2013 January 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/FORM_NO_10F-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">FORM NO 10F<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/StockExchangeIntimationInterimDividend202021-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation to Stock Exchange for considering Declaration of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/02\/IntimationofBoardMeetingQ3202021-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting January 2021<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/05\/StockExchangeIntimationSUNAZ28052021.pdf\" rel=\"attachment wp-att-9913\">StockExchangeIntimationSUNAZ28052021<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2020&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Webcast-Recording-of-28th-Annual-General-Meeting-of-the-Company-for-the-year-2019-20.docx\">Webcast Recording of 28th Annual General Meeting of the Company for the year 2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeofBoardMeetingQ2Nov032020Final.pdf\">Outcome of Board Meeting \u2013 November 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofBoardMeetingQ22020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting November 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/sam.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scheme of Amalgamation and Merger<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-CTC-BM-July-2020-for-SPGFZE-Merger-signed.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Board Resolution approving Scheme of Amalgamation and Merger<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/RPTDisclosure30092020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Related Party Disclosure on consolidated basis for the half year ended September 30, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Post-Buy-Back-Public-Announcement-September-26-2020.pdf\">Post Buy-Back Public Announcement \u2013 September 26, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofclosureofBuyback25092020.pdf\">Intimation of Closure of Buy Back \u2013 September 25, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Secretarial-Audit-Report-of-Material-Subsidiaries_2019-20.pdf\">Secretarial Audit Report of Material Subsidiaries_2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/VotingResults28thAGM.pdf\">Voting Results for the 28th Annual General Meeting and Scrutinizer\u2019s Consolidated Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-28th-Annual-General-Meeting.pdf\">Outcome of 28th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/28th-AGM-Speech.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman Speech at the 28th Annual General Meeting held on 27 August 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/CoveringletterforNewspaperSubmissionFinal.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice of 28th Annual General Meeting, E-voting and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY2019-20-1.pdf\">BUSINESS RESPONSIBILITY REPORT -FY2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Self-Declaration-Format-for-Non-Resident-Shareholders.pdf\">Self Declaration Format for Non-Resident Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-the-28th-Annual-General-Meeting.pdf\">Notice of the 28th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-AR-2019-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL ANNUAL REPORT -FY2019-20<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEME-Disclosure-under-SEBI-Share-Based-Employee-BenefitsRegulations2014-as-on-Mar-312020.pdf\">EMPLOYEES\u2019 STOCK OPTION SCHEME-Disclosure under SEBI (Share Based Employee Benefits)Regulations2014 as on Mar 312020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Upadate-on-Intimation-under-Regulation-30-of-Listing-Regulations.pdf\">Update on Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Final-Dividend-for-financial-year-2019-2020_Final.pdf\">Form for waiver-forgoing right to receive Final Dividend for financial year 2019-2020_Final<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-under-Regulation-30-of-Listing-Regulations.pdf\">Intimation under Regulation 30 of Listing Regulations<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome31072020.pdf\">Outcome of the Board Meeting &#8211; July 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofnewspaperpublicationforIEPF.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice for transfer of equity shares and unclaimed Dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SEIntimationofBM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting July 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/RPTDisclosureIntimationtoSE.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Related Party Disclosure on consolidated basis for the half year ended March 31, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Financials27052020FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting \u2013 May 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationofBoardMeeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting May 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Update-on-Halol-facility.pdf\">Stock Exchange Letter Update on Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Additional-details-for-OAI-classification-for-Halol-facility.pdf\">Additional details for OAI classification for Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Corrigendum-to-Public-Announcement-for-Buy-Back-of-Equity-Shares-March-24-2020.pdf\">Corrigendum to Public Announcement for Buy-Back of Equity Shares &#8211; March 24, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Public-Announcement-for-Buy-Back-of-Equity-Shares-\u2013-March-18-2020.pdf\">Public Announcement for Buy-Back of Equity Shares \u2013 March 18, 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-the-Board-Meeting-March-2020-Approval-of-Buy-Back.pdf\">Outcome of the Board Meeting March 2020 &#8211; Approval of Buy-Back<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stockexchangeintimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting March 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/StockExchangeIntimation06022020ID-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Intimation of Record Date for payment of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome06022020.pdf\">Outcome of the Board Meeting \u2013 February 2020<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Interim-Dividend-Waiver-Form_2019-20.pdf\">Interim Dividend Waiver Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILpriorIntimationtoStkExchangesforInterimDividend03022020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation to Stock Exchange for considering Declaration of Interim Dividend<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Intimation-of-Board-Meeting-February-2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting February 2020<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2019&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationToStockExchange.pdf\">Intimation to Stock Exchange for NCLT Order on Composite Scheme of Arrangement<\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationToStockExchange.pdf\">Update on US FDA Halol Inspection<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Antitrust-Litigation-in-US.pdf\">Stock Exchange Letter Antitrust Litigation in US<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-November-2019.pdf\">Outcome of Board Meeting &#8211; November 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationofBoardMeeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Intimation of Board Meeting November 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Related-Party-Disclosure-on-consodilated-basis-for-half-year-ended-September-30-2019.pdf\">Related Party Disclosure on consodilated basis for half year ended September 30, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/27thAGMSpeech.pdf\">Chairman Speech at the 27th Annual General Meeting held on August 28, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-August-2019.pdf\">Outcome of Board Meeting &#8211; August 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationofBoardMeeting-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification\/Confirmation on News Item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/LettertoSESPILNewspaperadvt.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement for Notice of 27th Annual General Meeting, E-voting and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILSEIntimationofBMAugust2019.pdf\">SPIL Intimation of Board Meeting August 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILIntimationBookClosureAGM.pdf\">SPIL Intimation of AGM date and Book Closure<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEMES-Disclosure-under-SEBI-Share-Based-Employee-Benefits-Regulations-2014-as-on-March-31-2019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">EMPLOYEES\u2019 STOCK OPTION SCHEMES &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Business-Responsibility-Report-FY2018-19.pdf\">Business Responsibility Report FY2018-19<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Dividend-Waiver-Form_2018-19.pdf\">Dividend Waiver Form 2018-19<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Voting-Results-alongwith-Scrutinizers-Report-of-TCM-held-on-June-04-2019.pdf\">Voting Results alongwith Scrutinizer\u2019s Report of TCM held on June 04, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Proceedings-of-the-NCLT-Convened-Meeting-of-Shareholders-and-Unsecured-Creditors-2019.pdf\">Proceedings of the NCLT Convened Meeting of Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-clarification-on-news-item-2019.pdf\">Stock Exchange clarification on news item<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ScrutinizerReportVotingResults.pdf\">Scrutinizer Report SPIL NCLT Meeting 04 06 2019 Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Advertisement-for-Notice-for-transfer-of-equity-shares-and-unclaimed-dividend-to-IEPF-2019.pdf\">Advertisement for Notice for transfer of equity shares and unclaimed dividend to IEPF<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Notice-of-Tribunal-Convened-Meeting_Unsecured-Creditors_June-04-2019.pdf\">Notice of Tribunal Convened Meeting Unsecured Creditors June 04, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Outcome-of-the-Board-Meeting-May-28-2019.pdf\">Outcome of the Board Meeting &#8211; May 28, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/SPIL-Intimation-of-BM-May-2019.pdf\">SPIL Intimation of BM May 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-information-of-Advertisement-2019.pdf\">Stock Exchange Intimationm Of Advertisement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-\u2013-Attendance-Slip-for-NCLT-Convened-Meeting-for-Equity-Shareholders-2019-1.pdf\">Sun Pharma \u2013 Attendance Slip for NCLT Convened Meeting for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Sun-Pharma-\u2013-Notice-of-NCLT-Convened-Meeting-including-Proxy-Form-and-Attendance-Slip-for-Equity-Shareholders-2019-1.pdf\">Sun Pharma &#8211; Notice of NCLT Convened Meeting including Proxy Form and Attendance Slip for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-\u2013-Proxy-Form-for-NCLT-Convened-Meeting-for-Equity-Shareholders.pdf\">Sun Pharma \u2013 Proxy Form for NCLT Convened Meeting for Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Related-Party-Disclosure-on-consodilated-basis-for-half-year-ended-September-30-2019-1.pdf\">Related Party Disclosure on consolidated basis for half year ended 31st March, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-the-Board-Meeting-February-12-2019.pdf\">Notice of Board Meeting &#8211; February 12, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-the-Board-Meeting-February-12-2019-2.pdf\">Outcome of the Board Meeting &#8211; February 12, 2019<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Observation-Letter-BSE.pdf\">Observation Letter \u2013 BSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Observation-Letter-NSE.pdf\">Observation Letter \u2013 NSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Sun-Pharma-Investor-Update.pdf\">Stock Exchange Letter Sun Pharma Investor Update<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-Letter-to-SEBI-on-alleged-second-whistleblower-complaint-filed-against-Sun.pdf\">Stock Exchange Letter to SEBI on alleged second whistleblower complaint filed against Sun<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-update-on-commercialsed-XELPROS-in-US.pdf\">Stock Exchange Letter update on commercialsed XELPROS in US<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Completion-of-transaction-Pola-Pharma-Japan.pdf\">Stock Exchange Letter Completion of transaction Pola Pharma, Japan<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2018&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Clarification-on-Recent-Media-Reports.pdf\">Stock Exchange Letter Clarification on Recent Media Reports<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-under-Regulation-30-of-the-SEBI-Listing-Obligations-and-Disclosure-Requirements-Regulations-2015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Intimation-of-settlement-in-re-Modafinil-Antitrust-Litigation-in-US-with-certain-plaintiffs.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter Intimation of settlement in re Modafinil Antitrust Litigation in US with certain plaintiffs<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-meeting-\u2013-Nov-13-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board meeting &#8211; Nov 13, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-meeting-\u2013-Nov-13-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board meeting &#8211; Nov 13, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-regarding-inter-se-change-in-shareholding-of-promoter-group-pursuant-to-Scheme-of-Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation regarding inter-se change in shareholding of promoter group pursuant to Scheme of Amalgamation.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-National-Stock-Exchange-of-India-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-BSE-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Shareholding-Patter-\u2013-September-30-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Shareholding Pattern &#8211; September 30, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Investor-\u2013-Shareholder-Information-\u2013-Statutory-Communications-\u2013-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Investor &#8211; Shareholder Information &#8211; Statutory Communications \u2013 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Results-of-26th-Annual-General-Meeting-to-Stock-Exchanges-along-with-Scrutinizers-Report.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Voting Results of 26th Annual General Meeting to Stock Exchanges along with Scrutinizers Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Composite-Scheme-of-Arrangement-1.pdf\">Composite Scheme of Arrangement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Chairman-speech-at-26th-Annual-General-Meeting-held-on-September-26-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman speech at 26th Annual General Meeting held on September 26, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-26th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Proceedings of 26th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-Mohali-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification to Stock Exchanges on Mohali facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-news-regarding-Halol-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification to Stock Exchanges on news regarding Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement.pdf\">Newspaper Advertisement &#8211; Notice of 26th AGM, E-voting and Book Closure &#8211; English and Gujarati<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY2017-18.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report FY2017-18<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receice-Dividend-for-financial-year-ended-31032018.pdf\">Form for waiver-forgoing right to receive Dividend for financial year ended March 31, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/EMPLOYEES-STOCK-OPTION-SCHEMES-\u2013-Disclosure-under-SEBI-Share-Based-Employee-Benefits-Regulations-2014-as-on-March-31-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">EMPLOYEES\u2019 STOCK OPTION SCHEMES &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-26th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of 26th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-of-Book-closure-and-AGM-date.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Book closure and AGM date<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeBM14082018.pdf\">Outcome of Board Meeting &#8211; August 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-\u2013-August-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting &#8211; August 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Clarification-to-Stock-Exchanges-on-news-regarding-Halol-facility-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification on news regarding Halol<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/VotingResultNCLTmeeting01062018-1.pdf\">Voting Results of NCLT Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-NCLT-Meetings-1.pdf\">Proceedings of National Company Law Tribunal Meetings held on June 01, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcomeallotmentcomm24052018.pdf\">Outcome of Board Meeting May 25, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeBoardMeetingMay_25_2018.pdf\">Notice of Board Meeting &#8211; May 25, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/AllotmentofEquityshares.pdf\">Allotment of Equity Shares under SUN ESOS 2015 &#8211; May 24, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-ad-Notice-for-NCLT-Convened-Meeting-of-Equity-Shareholders-Unsecured-Creditors-and-Notice-for-Remote-E-Voting-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice for NCLT Convened Meeting of Equity Shareholders &amp; Unsecured Creditors and Notice for Remote E-Voting for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Shareholding-Pattern-2018.pdf\">Shareholding Pattern<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\">SPIL &#8211; Attendance Slip for NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Unsecured-Creditors.pdf\">SPIL &#8211; NCLT Convened Meeting Notices of Unsecured Creditors along with Proxy Form and Attendance Slip<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Attendance-Slip-for-NCLT-Convened-Meeting-of-Equity-Shareholders-1.pdf\">SPIL &#8211; Attendance Slip for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-NCLT-Convened-Meeting-Notices-of-Equity-shareholders-along-with-Proxy-Form.pdf\">SPIL &#8211; NCLT Convened Meeting Notices of Equity shareholders along with Proxy Form<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/IntimationtostockexchangesMar102018.pdf\">Intimation to stock exchanges Mar 10 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-Update-on-USFDA-Halol-Inspection.pdf\">Update on USFDA Halol Inspection<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-to-Stock-Exchanges-under-Regulation-30-\u2013-Updates.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure to Stock Exchanges under Regulation 30 \u2013 Updates<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board Meeting &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allotment-of-Equity-Shares-under-SUN-ESOS-2015-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Allotment of Equity Shares under SUN ESOS 2015 &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-BSE-on-News-Clarification-Ankleshwar-unit-Feb-5-2018.pdf\">SPIL Reply to BSE on News Clarification Ankleshwar unit Feb 5 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-NSE-on-News-Clarification-Ankleshwar-unit-Feb-5-2018.pdf\">SPIL Reply to NSE on News Clarification Ankleshwar unit Feb 5, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-\u2013-February-14-2018.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting &#8211; February 14, 2018<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-to-Stock-Exchanges-under-Regulation-30-\u2013-Updates-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure to Stock Exchanges under Regulation 30 \u2013 Updates<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2017&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-Regulations-2015.pdf\">Scheme of Arrangement &#8211; Compliance of Regulation 37 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/disclosure-to-stock-exchange-under-regulation.pdf\">Disclosure to Stock Exchanges under Regulation 30<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcome-of-board-meeting_14-november-2017.pdf\">Outcome of Board Meeting 14 November 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcomeof-allottment-commitee-meeting_14-november-2017.pdf\">Outcome of Allotment Committee Meeting 14 November 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-November-14-2017.pdf\">Notice of Board Meeting &#8211; November 14 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/outcome-of-allotment-commitee-sept26-2017.pdf\">Outcome of Allottment Commitee Meeting September 26 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-US-FDA-Dadra-Inspection.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on US FDA Dadra Inspection<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/votingresultsfor25thagm.pdf\">Voting Results for the 25th AGM and Scrutinizers Report<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Chairman-and-Managing-Director-Speech-at-25th-Annual-General-Meeting-held-on-September-26-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chairman and Managing Director Speech at 25th Annual General Meeting held on September 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-25th-AGM.pdf\">Proceedings of 25th Annual General Meeting<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-English-Ahmedabad-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure English Ahmedabad Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-English-Mumbai-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure English Mumbai Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-Notice-of-AGM-Evoting-and-Book-Closure-Gujarati-Ahmedabad-Edition.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement Notice of AGM Evoting and Book Closure Gujarati Ahmedabad Edition<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-of-right-to-receive-Dividend-for-the-financial-year-ended-March-31-2017.pdf\">Form for waiver-forgoing of right to receive Dividend for the financial year ended March 31 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2016-17.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ESOS-Disclosure-under-SEBI-SBEB-Regulations-2014-as-on-March-31-2017.pdf\">ESOS &#8211; Disclosure under SEBI (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-25th-AGM-2016-17.pdf\">SPIL Notice of 25th AGM 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL_Attendance_Slip_ProxyForm-_2016-17.pdf\">SPIL Attendance Slip and Proxy Form 2016-17<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Outcome-of-Allottment-Commitee-Meeting_August-11-2017-1.pdf\">Outcome of Allottment Commitee Meeting August 11, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting_August-11-2017-1.pdf\">Outcome of Board Meeting August 11, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting_August-11-2017.pdf\">Notice of Board Meeting August 11 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimation-of-change-in-key-managerial-person-for-determining-materiality-of-an-event-or-information.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of change in key managerial person for determining materiality of an event or information<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Proceedings-of-NCLT-Convened-Meetings-held-on-June-20-2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Proceedings of NCLT Convened Meetings held on June 20, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scrutinizers-Report-for-the-NCLT-Convened-Meeting-of-Unsecured-Creditors.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Scrutinizer&#8217;s Report for the NCLT Convened Meeting of Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Consolidated-Scrutinizers-Report-for-the-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Consolidated Scrutinizer&#8217;s Report for the NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Results-of-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Voting Results of NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Correction-Letter-to-the-Letter-to-Stock-Exchange-for-outcome-of-Board-Meeting-May-26-2017.pdf\">Correction Letter to the Letter to Stock Exchange for outcome of Board Meeting May 26 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting_May-26-2017.pdf\">Outcome of Board Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Allottment-Commitee-Meeting_May-26-2017.pdf\">Outcome of Allottment Commitee Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-regarding-Notice-for-Postal-Ballot-and-Remote-E-voting-for-the-National-Company-Law-Tribunal-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice for Postal Ballot and Remote E-voting for the National Company Law Tribunal Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Newspaper-Advertisement-regarding-Notice-of-the-National-Company-Law-Tribunal-Convened-Meetings-of-Equity-Shareholders-and-Unsecured-Creditors.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Newspaper Advertisement regarding Notice of the National Company Law Tribunal Convened Meetings of Equity Shareholders and Unsecured Creditors<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting_May_26_2017.pdf\">Notice of Board Meeting May 26, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-NCLT-Convened-Meeting-of-Equity-shareholders-Proxy-Attendance-Slip.pdf\">Notice of NCLT Convened Meeting of Equity Shareholders including Proxy Form and Attendance Slip<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Tribunal-Convened-Meeting-of-Unsecured-Creditors-of-the-Company.pdf\">Notice of Tribunal Convened Meeting of Unsecured Creditors of the Company<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-for-NCLT-Convened-Meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Form for NCLT Convened Meeting of Equity Shareholders<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Acquisition-of-Thallion-Pharmaceuticals-Inc..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Thallion Pharmaceuticals Inc.<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/BSE-Observation-letter.pdf\">Observation letter \u2013 BSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NSE-observation-letter.pdf\">Observation letter \u2013 NSE<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-Board-Meeting-February-14-2-2017.pdf\">Outcome of Board Meeting February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allottment-Commitee-Meeting-Outcome-of-Meeting-February-14-2-2017.pdf\">Allottment Commitee Meeting Outcome of Meeting February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeofBoardMeeting14022017.pdf\">Notice of Board Meeting &#8211; February 14, 2017<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ComplaintReportNSE.pdf\">Complaint Report filed by the Company to National Stock Exchange of India Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Complaint-Report-filed-by-the-Company-to-BSE-Limited-pursuant-to-filing-of-Draft-Scheme-of-Arrangement-for-Amalgamation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Complaint Report filed by the Company to BSE Limited pursuant to filing of Draft Scheme of Arrangement for Amalgamation<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2016&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Reply-to-BSE-on-news-clarification-Ahmednagar-unit-Dec-29-2016-rev.pdf\">SPIL Reply to BSE on news clarification Ahmednagar unit Dec 29, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILReplytoNSEonnewsclarificationAhmednagarunitDec292016.pdf\">SPIL Reply to NSE on news clarification Ahmednagar unit Dec 29, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Disclosure-under-Regulation-30-of-the-SEBI-Listing-Obligations-and-Disclosure-Requirements-Regulations-2015-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-Compliance-of-Regulation-37of-SEBI-Listing.pdf\">Scheme of Arrangement &#8211; Compliance of Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-acquisition-of-Ocular-Technologies-Sarl-\u2013-closure-of-transaction-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Update on acquisition of Ocular Technologies, Sarl \u2013 closure of transaction<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-\u2013-Reply.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter \u2013 Reply<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-\u2013-Update-on-USFDA-Inspection-for-Halol-facility.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Letter &#8211; Update on USFDA Inspection for Halol facility<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-to-acquire-Biosintez-in-Russia.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sun Pharma to acquire Biosintez in Russia<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Allottment-Commitee-Meeting_Outcome-of-Meeting.pdf\">Allottment Commitee Meeting Outcome of Meeting<\/a><\/p>\n<p><span><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Stock-Exchange-Intimation-on-CFO-2016.pdf\">Stock Exchange Intimation on CFO<\/a><\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Board-Meeting-10th-November-2016.pdf\">Notice of Board Meeting &#8211; 10th November, 2016<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Change-in-Window-Closure-Date-for-trading-by-Designated-Persons.pdf\">Change in Window Closure Date for trading by Designated Persons<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Completion-of-Buyback-and-Submission-of-Post-Buyback-Public-Announcement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Completion of Buyback and Submission of Post Buyback Public Announcement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Submission-of-Corrigendum-to-the-Post-Buyback-Public-Announcement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Submission of Corrigendum to the Post Buyback Public Announcement<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Receipt-of-approval-for-reclassification-of-shares-under-Regulation-31A7-of-the-SEBI-Listing-Obligation-Disclosure-Requirements-Regulations-2015.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Receipt of approval for reclassification of shares under Regulation 31A(7) of the SEBI (Listing Obligation &amp; Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILSubmissionofAOA.pdf\">Submission of new set of Articles of Association of the Company<\/a><\/p>\n<p><span>September 22, 2016<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL24thAGMVOTINGRESULTS.pdf\">Voting Results of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPILProceedingsAGM17092016.pdf\">Proceedings of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SCRUTINIZERS-REPORT.pdf\">Srcutinizer&#8217;s Report on Voting Results of 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/24th-AGM-Speech-Sept-2016.pdf\">Chairman and Managing Director Speech at 24th Annual General Meeting held on September 17, 2016<\/a><\/p>\n<p>September 19, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Buyback-LOF.pdf\">Letter of offer for Buyback<\/a><\/p>\n<p>September 14, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL_Draft-AOA-with-proposed-amendments.pdf\">Draft Articles of Association of SPIL<\/a><\/p>\n<p>August 27, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receice-Dividend-for-financial-year-ended-31032016-final.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-16<\/a><\/p>\n<p>August 18, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-24th-AGM-2016.pdf\">NOTICE OF 24th ANNUAL GENERAL MEETING<\/a><\/p>\n<p>August 17, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-BRR.pdf\">Business Responsibility Report 2015-16<\/a><\/p>\n<p>August 17, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/STOCKEXCHANGEINTIMATION.pdf\">Notice of Board meeting scheduled on August 12, 2016<\/a><\/p>\n<p>August 05, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/P.1-2-Draft-Letter-of-Offer-Sun-Pharmaceutical-Industries-Ltd-Buyback.pdf\">Draft letter of offer for Buyback &#8211; Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>July 08, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Public-Announcement-Sun-Pharmaceutical-Industries-Limited-Buyback-through-Tender-Offer-Route.pdf\">Public Announcement of Sun Pharmaceutical Industries Limited for buyback through Tender Offer<\/a><\/p>\n<p>June 28, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/OutcomeJune232016.pdf\">Outcome of Board Meeting dated June 23, 2016<\/a><\/p>\n<p>June 23, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-BM-30.05.2016.pdf\">Outcome of the Board meeting held on 30th May, 2016<\/a><\/p>\n<p>May 30, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Intimationforreclassificationofpromoter23052016.pdf\">Intimation pertaining to Request letter(s) received from certain Promoter group under Regulation 31A of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015<\/a><\/p>\n<p>May 23, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/BMINTIMATION30.05.2016.pdf\">Notice of Board meeting scheduled on 30th May, 2016<\/a><\/p>\n<p>May 13, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-intimation-of-withdrawal-of-credit-rating.pdf\">Intimation of withdrawal of CARE rating at Company\u2019s request<\/a><\/p>\n<p>April 07, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Announcement.pdf\">Termination of collaboration established in 2011 between affiliates of Merck Sharp &amp; Dohme and Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>February 15, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Outcome-of-BM-12.02.2016.pdf\">Outcome of the Board meeting held on 12th February, 2016<\/a><\/p>\n<p>February 12, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SEINTIMATIONBM31122015SPIL.pdf\">Notice of Board Meeting scheduled on 12th February 2016<\/a><\/p>\n<p>January 29, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Intimation-to-Stock-Exchanges_Jan-22-2016-regarding-CCI-approval-for-sale-of-CNS-division.pdf\">CCI approval for sale of CNS division to Strides<\/a><\/p>\n<p>January 22, 2016<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/Disclosure-Regarding-Stock-Exchanges-Under-Regulation-30-Nov-22-2016.pdf\">Disclosure to Stock Exchanges under Regulation 30<\/a><\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2015&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Authorized-KMP-to-determine-materiality-of-event-or-information.pdf\">Authorized KMPs for determining materiality of an event or information<\/a><\/p>\n<p>November 30, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Update-on-Wind-Energy-Project.pdf\">Update on Wind Energy Project<\/a><\/p>\n<p>November 24, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Result-of-Postal-Ballot-as-per-Clause-35A_06.11.2015.pdf\">Result of Postal Ballot as per Clause 35A of the Listing Agreement alongwith Scrutinizers Report<\/a><\/p>\n<p>November 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20151102-Report-on-Proceedings-of-23rd-AGM-with-Scrutinizer-report-_-voting-results.pdf\">Report on Proceedings of 23rd AGM with Scrutinizer report &amp; voting results<\/a><\/p>\n<p>November 02, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/23rd-AGM-Chairman-Speech-31Oct-2015.pdf\">23rd AGM Chairman Speech<\/a><\/p>\n<p>October 31, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Dividend-for-year-end-31-03-15.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-15<\/a><\/p>\n<p>October 20, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Notice-of-23rd-AGM-2015.pdf\">Notice of 23rd Annual General Meeting<\/a><\/p>\n<p>October 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-FY14-15_0.pdf\">Business Responsibility Report 2014-15<\/a><\/p>\n<p>October 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/NoticeofPostalBallotForm.pdf\">Notice of Postal Ballot &amp; Postal Ballot form<\/a><\/p>\n<p>October 05, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Voting-Result-of-Court-Convened-Meeting-of-SPIL-to-consider-the-Scheme-of-Merger-of-SPGI-with-the-Company.pdf\">Voting Result of Court Convened Meeting of SPIL to consider the Scheme of Merger of SPGI with the Company<\/a><\/p>\n<p>June 06, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-for-Court-Convened-Meeting_SPIL_SPGI.pdf\">Notice for the Court convened meeting for approval of the Scheme of Merger of Sun Pharma Global Inc with Sun Pharmaceutical Industries Ltd.<\/a><\/p>\n<p>May 18, 2015<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Draft-Scheme-of-Amalgamation-_-other-documents.pdf\">Draft Scheme of Amalgamation and other documents pertaining to the proposed merger of Sun Pharma Global Inc. with the Company<\/a><\/p>\n<p>March 12, 2015<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2014&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/ClarificationregardingCCIapproval.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Clarification regarding CCI approval to the Scheme of Arrangement between Ranbaxy and Sun Pharma<\/a><\/p>\n<p>December 01, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/SPIL-Outcome-of-22nd-AGM-2014-Voting-Results-as-per-35AScrutinizer-Reports-1.pdf\">Outcome of 22nd AGM 2014, Voting Results as per 35A and Scrutinizer Reports<\/a><\/p>\n<p>October 01, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/22th-AGM-Chairman-Speech-Sep-2014_0-1.pdf\">22nd AGM Chairman Speech<\/a><\/p>\n<p>September 29, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Sun-Pharma-AGM-Notice-2013-14-1.pdf\">Notice of 22nd Annual General Meeting<\/a><\/p>\n<p>September 04, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-IV-2.pdf\">Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)<\/a><\/p>\n<p>September 04, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2013-14-1.pdf\">Business Responsibility Report 2013-14<\/a><\/p>\n<p>September 02, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Letter-CCI-Communication-1.pdf\">Intimation pertaining to communication from the Competition Commission of India (CCI)<\/a><\/p>\n<p>August 27, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/CCM-Voting-Results-1.pdf\">Outcome of Court Convened Meeting &amp; Poll Results<\/a><\/p>\n<p>August 26, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Form-for-waiver-forgoing-right-to-receive-Dividend-for-Y.E.31-03-14-1.pdf\">Form for waiver forgoing right to receive Dividend for year ended 31-03-14<\/a><\/p>\n<p>August 26, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Notice-of-Court-Convened-Meeting-on-22.08.2014-Scheme-ExplStmt-Attd-Slip-_-Proxy-Form-1.pdf\">Notice of Court Convened Meeting on 22.08.2014, Scheme, ExplStmt, Attd Slip &amp; Proxy Form<\/a><\/p>\n<p>July 29, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-Arrangement-between-Ranbaxy-_-Sun-Pharma-1.pdf\">Scheme of Arrangement between Ranbaxy Laboratories Limited And Sun Pharmaceutical Industries Limited<\/a><\/p>\n<p>May 12, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20140509-Proceedings-of-Court-convened-Meeting-of-Equity-Shareholders-held-on-May-05-2014-1.pdf\">Proceedings &amp; Results of Court convened Meeting of Equity Shareholders held on May 05, 2014<\/a><\/p>\n<p>May 09, 2014<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Scheme-of-arrangement-reconstruction-between-SunPharma-GlobalFZE-SunPharmaceuticalIndustriesLtd-1.pdf\">Scheme of arrangement &amp; reconstruction between Sun Pharma Global FZE &amp; Sun Pharmaceutical Industries Ltd.<\/a><\/p>\n<p>January 21, 2014<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2013&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/21-AGM-Chairman-Speech-Sep-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">21st AGM Chairman Speech<\/a><\/p>\n<p>October 01, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Business-Responsibility-Report-2012-13.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Business Responsibility Report 2012-13<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-Notice-of-Adjourned-Twentieth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Adjourned Twentieth Annual General Meeting<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130905-SPIL-Proxy-Form-_-Attendance-Slip..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip for Adjourned Twentieth AGM &amp; Twenty-first AGM<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130905-Notice-of-Twenty-first-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Twenty-first Annual General Meeting<\/a><\/p>\n<p>September 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130904-Form-for-waiver-forgoing-right-to-receive-Dividend-for-Y.E.-31-03-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form for waiver forgoing right to receive Dividend year ended 31-03-2013<\/a><\/p>\n<p>September 04, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130805-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>August 05, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130718-Intimation-regarding-Record-Date-Stock-Exchanges_0.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Intimation of Record Date for Bonus Shares<\/a><\/p>\n<p>July 18, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130715-Postal-Ballot-Result-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Result of Postal Ballot<\/a><\/p>\n<p>July 15, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130703-Quarterly-compliance-report-of-the-Corp.-Gov.30-06-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corporate Governance 30-06-2013<\/a><\/p>\n<p>July 03, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-30.05.2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Form 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Form-30.05.2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Request for Bonus Equity Share in Electronic Form &amp; Envelopes<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Postal-Ballot-Notice-30.05.2013-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Postal Ballot Notice 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Stock-Exchange-Intimation-10-06-13-Postal-Ballot.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Stock Exchange Intimation of Postal Ballot 30.05.2013<\/a><\/p>\n<p>June 10, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130401-Quarterly-compliance-report-of-the-Corp.-Gov.31-03-2013.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-03-2013<\/a><\/p>\n<p>April 01, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130123-Notice-of-Board-Meeting-for-quarter-end-31-12-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2012<\/a><\/p>\n<p>January 23, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130108-Notice-of-Convening-the-meeting-of-Equity-Shareholders.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Convening the meeting of Equity Shareholders<\/a><\/p>\n<p>January 08, 2013<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20130109-Quarterly-compliance-report-of-the-Corp.-Gov.31-12-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-12-2012<\/a><\/p>\n<p>January 07, 2013<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2012&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/Code-of-Conduct-SPIL-as-on-31.03.2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Code of Conduct for Directors and Senior Management<\/a><\/p>\n<p>December 14, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121022-Notice-of-Board-Meeting-for-quarter-end-30-09-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2012<\/a><\/p>\n<p>October 22, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121012-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 12, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-Notice-of-Twentieth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Twentieth Annual General Meeting<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121011-Notice-for-20th-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice for 20th Annual General Meeting<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120811-SPIL-Proxy-Form-_-Attendance-Slip.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip<\/a><\/p>\n<p>October 11, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121010-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 10, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121015-Quarterly-compliance-report-of-the-Corp.-Gov.30-09-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.30-09-2012<\/a><\/p>\n<p>October 09, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121004-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>October 04, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20121003-Rising-Funds-_-Fixation-of-Book-Closure-Date.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Rising Funds &amp; Fixation of Book Closure Date<\/a><\/p>\n<p>October 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120927-Disclosure-UR-13-6-of-the-SEBI-Prohibition-of-Insider-Trading.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Disclosure UR 13 (6) of the SEBI Prohibition of Insider Trading<\/a><\/p>\n<p>September 27, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120813-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2012..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2012<\/a><\/p>\n<p>August 13, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120807-Intimation-Restructuring-Interim-Dividend-_-Record-Date-SPIL-3-8-12.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation Restructuring, Interim Dividend &amp; Record Date 3-8-12<\/a><\/p>\n<p>August 06, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120703-Quarterly-compliance-report-of-the-Corp.-Gov.30-06-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.30-06-2012<\/a><\/p>\n<p>July 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120416-Clause-47-c-of-the-Listing-Agreement.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Intimation of Compliance as per Clause 47 (c) as on 31.03.2012<\/a><\/p>\n<p>April 24, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120403-Quarterly-compliance-report-of-the-Corp.-Gov.31-03-2012.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-03-2012.pdf<\/a><\/p>\n<p>April 03, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120130-Notice-of-Board-Meeting-for-quarter-end-31-12-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2011<\/a><\/p>\n<p>January 30, 2012<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20120111-Quarterly-compliance-report-of-the-Corp.-Gov.31-12-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov.31-12-2010<\/a><\/p>\n<p>January 11, 2012<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2011&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Notice to acquire all the outstanding shares in Taro Pharma<\/p>\n<p>October 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20111018-Notice-of-Board-Meeting-for-quarter-end-30-09-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2011<\/a><\/p>\n<p>October 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20111013-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>October 13, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110927-Acquisition-of-Shares-_-Takeovers-code-intimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Shares &amp; Takeovers code intimation<\/a><\/p>\n<p>September 27, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110919-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>September 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110905-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2011.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2011<\/a><\/p>\n<p>September 05, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110819-SPIL-Proxy-Form-_-Attendance-Slip.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">SPIL Proxy Form &amp; Attendance Slip<\/a><\/p>\n<p>August 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110715-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>July 15, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110705-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>July 05, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110511-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>May 11, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110511-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>May 11, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110819-Notice-of-Nineteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Nineteenth Annual General Meeting<\/a><\/p>\n<p>April 19, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110330-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 30, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110218-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>February 18, 2011<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20110128-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>January 28, 2011<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2010&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20101112-Result-of-the-Postal-Ballot.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Result of the Postal Ballot<\/a><\/p>\n<p>November 12, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20101111-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>November 11, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100923-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>September 30, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/18th-AGM-Chairman-Speech-Sep-2010-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">18th AGM Chairman Speech<\/a><\/p>\n<p>September 26, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100924-Notice-of-Proceedings-18th-AGM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Proceedings Eighteenth AGM<\/a><\/p>\n<p>September 24, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100924-Notice-Split-of-Shares-fro-Rs.5-to-Re.1-per-share.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice Split of Shares fro Rs.5 to Re.1 per share<\/a><\/p>\n<p>September 24, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100907-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>September 07, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100901-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>September 01, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100819-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2010<\/a><\/p>\n<p>August 19, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100810-Fixation-of-Book-Closure-Date-for-payment-of-Dividend..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Fixation of Book Closure Date for payment of Dividend<\/a><\/p>\n<p>August 10, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100614-Notice-of-Eighteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Eighteenth Annual General Meeting<\/a><\/p>\n<p>June 14, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100901-Security-pledge-revocation-letter-Revoked1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>May 22, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100507-Notice-of-Board-Meeting-for-quarter-end-31-03-2010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-03-2010<\/a><\/p>\n<p>May 07, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100402-appointed-Shri.-Kal-Sundaram-as-an-additional-Director-on-the-Board.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Appointed Shri. Kal Sundaram, as an additional Director on the Board<\/a><\/p>\n<p>April 02, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100326-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 26, 2010<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20100104-Quarterly-compliance-report-of-the-Corp.-Gov.-31-12-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 31-12-2009<\/a><\/p>\n<p>January 04, 2010<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2009&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091218-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>December 18, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/01\/20091103-Security-pledge-revocation-letter-Pledged-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>November 03, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091020-Security-pledge-revocation-letter-Revoked-_-Pledged-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>October 20, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20091010-Notice-of-Board-Meeting-for-quarter-end-30-09-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 30-09-2009<\/a><\/p>\n<p>October 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090914-Notice-for-expiry-of-HSR-waiting-period-in-U.S.-for-Taro-Tender-Offer.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice for expiry of HSR waiting period in U.S. for Taro Tender Offer<\/a><\/p>\n<p>September 14, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090912-Acquisition-of-Shares-_-Takeovers-code-intimation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Acquisition of Shares &amp; Takeovers code intimation<\/a><\/p>\n<p>September 12, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090912-Notice-of-Proceedings-17th-AGM.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Proceedings Seventeenth AGM<\/a><\/p>\n<p>September 12, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/17th-AGM-Chairman-Speech-Sep-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">17th AGM Chairman Speech<\/a><\/p>\n<p>September 11, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090810-Security-pledge-revocation-letter-Revoked-_-Pledged.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked &amp; Pledged)<\/a><\/p>\n<p>August 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090711-Notice-of-Seventeenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Seventeenth Annual General Meeting<\/a><\/p>\n<p>July 11, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090702-Quarterly-compliance-report-of-the-Corp.-Gov.-30-06-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 30-06-2009<\/a><\/p>\n<p>July 02, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090530-Outcome-of-Board-meeting-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Outcome of Board meeting 31-03-2009<\/a><\/p>\n<p>May 30, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090420-Details-of-share-holding-in-terms-of-Regulation-83-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Details of share holding, in terms of Regulation 8(3)<\/a><\/p>\n<p>April 20, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090407-Quarterly-compliance-report-of-the-Corp.-Gov.-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 31-03-2009<\/a><\/p>\n<p>April 07, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090731-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2009.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Form of Waiverforgoing the Right to receive the dividend 31-03-2009<\/a><\/p>\n<p>March 31, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090313-Security-pledge-revocation-letter-Revoked.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Revoked)<\/a><\/p>\n<p>March 13, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090210-Security-pledge-revocation-letter-Pledged-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Security pledge revocation letter (Pledged )<\/a><\/p>\n<p>February 10, 2009<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20090116-Notice-of-Board-Meeting-for-quarter-end-31-12-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Notice of Board Meeting for quarter end 31-12-2008<\/a><\/p>\n<p>January 16, 2009<\/p>\n<p>[\/et_pb_tab][et_pb_tab title=&#8221;2008&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20081003-Quarterly-compliance-report-of-the-Corp.-Gov.-30-09-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quarterly compliance report of the Corp. Gov. 30-09-2008<\/a><\/p>\n<p><span>October 03, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/16th-AGM-Chairman-Speech-Sep-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>16th AGM Chairman Speech<\/span><\/a><\/p>\n<p><span>September 06, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080827-Notice-of-Sixteenth-Annual-General-Meeting.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Notice of Sixteenth Annual General Meeting<\/span><\/a><\/p>\n<p><span>August 27, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080808-Form-of-Waiverforgoing-the-Right-to-receive-the-dividend-31-03-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Form of Waiverforgoing the Right to receive the dividend 31-03-2008<\/span><\/a><\/p>\n<p><span>August 08, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080412-Quarterly-compliance-report-of-the-Corp.-Gov.-31-03-2008.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Quarterly compliance report of the Corp. Gov. 31-03-2008<\/span><\/a><\/p>\n<p><span>April 12, 2008<\/span><\/p>\n<p><a href=\"https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2020\/12\/20080320-Allotment-of-Equity-Shares-against-conversion-of-further-FCCBs.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><span>Allotment of Equity Shares against conversion of further FCCBs<\/span><\/a><\/p>\n<p><span>March 20, 2008<\/span><\/p>\n<p><span><\/span><\/p>\n<p>[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Statutory CommunicationsScrutinizer Report of Postal Ballot E-voting April 2026 Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon &#038; Co. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-3333","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical<\/title>\n<meta name=\"description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical\" \/>\n<meta property=\"og:description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T14:22:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u05d6\u05de\u05df \u05e7\u05e8\u05d9\u05d0\u05d4 \u05de\u05d5\u05e2\u05e8\u05da\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 \u05d3\u05e7\u05d5\u05ea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\",\"name\":\"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"datePublished\":\"2020-12-14T07:30:23+00:00\",\"dateModified\":\"2026-05-08T14:22:28+00:00\",\"description\":\"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/investors-statutory-communications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors &#8211; Statutory Communications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","og_locale":"he_IL","og_type":"article","og_title":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","og_description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","og_url":"https:\/\/dev.sunpharma.com\/he\/investors-statutory-communications\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_modified_time":"2026-05-08T14:22:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u05d6\u05de\u05df \u05e7\u05e8\u05d9\u05d0\u05d4 \u05de\u05d5\u05e2\u05e8\u05da":"17 \u05d3\u05e7\u05d5\u05ea"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/","url":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/","name":"Shareholder\u2019s Information | Statutory Communications - Sun Pharmaceutical","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"datePublished":"2020-12-14T07:30:23+00:00","dateModified":"2026-05-08T14:22:28+00:00","description":"At Sun, we remain committed to creating long term value for our shareholders Statutory Communications. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/investors-statutory-communications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/investors-statutory-communications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Investors &#8211; Statutory Communications"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=3333"}],"version-history":[{"count":277,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333\/revisions"}],"predecessor-version":[{"id":18939,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/3333\/revisions\/18939"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=3333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}